Retatrutide 20 mg
Triple GIP / GLP-1 / Glucagon Agonist
$140CAD · 20 mg vial
Purity ≥ 99%LyophilizedCOA included
A higher-capacity 20 mg presentation of the triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors — an emerging frontier in metabolic and adiposity research.
Choose pack
1
Research applications
- Triple-incretin receptor mechanisms
- Energy-expenditure and lipolysis models
- Glycemic-control research
For laboratory research use only. Not for human consumption.